Table 1.
Clinical parameters, hormonal biomarkers, tumor grade, Ki-67 labelling index, lymph node metastases, extra nodal extension, and pTNM status
| Group | Feature | Frequency | Percentage | |
|---|---|---|---|---|
| pT3N3a | 3 | 8.57 | ||
| Age (years), N=114 | 20-60 | 81 | 71.05 | |
| Elderly (>60) | 33 | 29.84 | ||
| Gender, N=114 | Female | 112 | 98.25 | |
| Male | 02 | 1.75 | ||
| Menstrual history (N=112) | Pre-menopausal | 45 | 40.18 | |
| Post-menopausal | 67 | 59.82 | ||
| Clinical features (N=114) | Pain | 39 | 34.21 | |
| Pain, lump | 75 | 65.79 | ||
| Chemotherapeutic intervention (N=114) | Yes | 28 | 24.56 | |
| No | 86 | 75.44 | ||
| Hormonal biomarkers (N=114) | ER | Positive | 65 | 57.02 |
| Negative | 49 | 42.98 | ||
| PgR | Positive | 49 | 42.98 | |
| Negative | 65 | 57.02 | ||
| Her2/ Neu | Positive | 47 | 41.23 | |
| Negative | 56 | 49.12 | ||
| Equivocal | 11 | 9.65 | ||
| Histological tumor grade (N=86) | Grade 1 | 11 | 9.65 | |
| Grade 2 | 58 | 50.88 | ||
| Grade 3 | 17 | 14.91 | ||
| Ki-67 labelling index (N=114) | <14 | 18 | 15.79 | |
| ≥14 | 96 | 84.21 | ||
| Lymph node metastases (N=63) | Positive | 42 | 67.74 | |
| Negative | 21 | 33.33 | ||
| Extranodal extension (ENE) (N=63) |
Positive | 13 | 20.63 | |
| Negative | 50 | 79.37 | ||
| pTNM status (N=35) | pT1cN0 | 1 | 2.86 | |
| pT2N0 | 15 | 42.86 | ||
| pT2N1a | 6 | 17.14 | ||
| pT2N2a | 4 | 11.43 | ||
| pT3N1a | 2 | 5.71 | ||
| pT3N2a | 2 | 5.71 | ||
| pT2N3a | 2 | 5.71 | ||